# Surufatinib

Source: https://onco.cc/drugs/surufatinib/  
OnCo record `surufatinib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Surufatinib is HUTCHMED's angio-immuno kinase inhibitor, approved in China in 2020 for non-pancreatic and in 2021 for pancreatic neuroendocrine tumours.

## Summary

Surufatinib (Sulanda) was discovered and developed by HUTCHMED in Shanghai. The NMPA approved it in December 2020 for unresectable locally advanced or metastatic, well-differentiated, non-pancreatic neuroendocrine tumours (SANET-ep trial) and in June 2021 for pancreatic neuroendocrine tumours (SANET-p trial). A US application was withdrawn in 2022 after the FDA asked for a multi-regional trial.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-16
- Also known as: sulfatinib; Sulanda
- Tags: china; nmpa-approved
- Code: HMPL-012
- Modality: Oral VEGFR, FGFR1 and CSF1R tyrosine kinase inhibitor
- Mechanism: Blocks the VEGF and FGF receptors that build tumour blood vessels and the CSF1 receptor on tumour-associated macrophages, cutting the tumour's blood supply and its immune shelter at once.
- Approvals: CN 2020: Advanced non-pancreatic neuroendocrine tumours; pancreatic neuroendocrine tumours from 2021

## Sources

- ClinicalTrials.gov: trials of surufatinib: https://clinicaltrials.gov/search?intr=surufatinib

## Connected records

- cancers: [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [CSF1R](https://onco.cc/targets/csf1r/), [VEGF / VEGFR](https://onco.cc/targets/vegf/)
- companies: [Hutchmed](https://onco.cc/companies/hutchmed/)

---
JSON: https://onco.cc/api/v1/entities/surufatinib.json